Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
| ▸ | THRA | P10827 | 2/20 | 0.38 |
| ▸ | THRB | P10828 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | AR | P10275 | 2/20 | 0.36 |
| ▸ | MAOB | P27338 | 2/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | GLRA1 | P23415 | 1/20 | 0.34 |
| ▸ | HPD | P32754 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL113290 | 0.87 | PTPN1 (0.39) | PTPN1THRATHRBLMNAHPGD | |
| SCHEMBL9289257 | 0.86 | MAPT (0.38) | THRATHRBLMNANPC1KMT2A | |
| SCHEMBL9287344 | 0.85 | PTPN1 (0.40) | PTPN1THRATHRBLMNAHPGD | |
| SCHEMBL9284201 | 0.84 | PTPN1 (0.40) | PTPN1THRATHRBLMNAHPGD | |
| SCHEMBL18523541 | 0.83 | PTPN1 (0.39) | PTPN1THRATHRBLMNAHPGD | |
| SCHEMBL9287286 | 0.81 | PTPN1 (0.40) | PTPN1THRATHRBLMNAHPGD | |
| SCHEMBL18525117 | 0.81 | PTPN1 (0.40) | PTPN1THRATHRBLMNAHPGD | |
| SCHEMBL9282794 | 0.80 | PTPN1 (0.38) | PTPN1THRATHRBLMNAHPGD | |
| SCHEMBL18511746 | 0.79 | PTPN1 (0.38) | PTPN1THRATHRBLMNAHPGD | |
| SCHEMBL18523335 | 0.79 | PTPN1 (0.38) | PTPN1THRATHRBLMNAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190077803-A1 | TETRACYCLINE COMPOUNDS | TETRAPHASE PHARMACEUTICALS INC (US) | 2019-03-14 | — | — | US | disclosed |
| US-20170044160-A1 | TETRACYCLINE COMPOUNDS | TETRAPHASE PHARMACEUTICALS, INC. | 2017-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170044160-A1 | TETRACYCLINE COMPOUNDS | TUBB, TUBA1C, TUBA1A | PTPN1 402/4885THRA 256/4885THRB 395/4885 |
| US-20190077803-A1 | TETRACYCLINE COMPOUNDS | TUBB, TUBA1C, TUBA1A | PTPN1 402/4885THRA 256/4885THRB 395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.